RxDoctor Payments Data

Felix Chion Fong, MD

General Practice · Miami, FLNPI 1255379186

Payments from drug & device makers

$510,649in general payments, 2019–2025

Across 327 payments — averaging $1561.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akcea Therapeutics, Inc.$192K
  • Esperion Therapeutics, Inc.$112K
  • American Regent$77K
  • Biohaven Pharmaceutical Holding Company Ltd.$50K
  • Biohaven Pharmaceuticals, Inc.$24K
  • GSK$15K
  • plus $40K from 9 others

What the payments were for

  • Food & beverage$130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$510,649 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$49,402
Medicare patients
79
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate58$36,636
FarxigaDapagliflozin Propanediol21$12,734
EliquisApixaban22$10,859
LinzessLinaclotide17$8,988
Tresiba Flextouch U-100Insulin Degludec15$7,156
XareltoRivaroxaban11$7,136
TradjentaLinagliptin13$6,603
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,059
VascepaIcosapent Ethyl23$5,657
BrilintaTicagrelor11$5,315
Rosuvastatin Calcium308$4,273
Quetiapine Fumarate ErQuetiapine Fumarate17$3,704
Memantine Hcl ErMemantine Hcl26$2,954
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm14$2,836
Atorvastatin Calcium513$2,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14,017$10,85922 claims
Boehringer IngelheimTradjenta, Pradaxa$13,064$8,64924 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$10,684$1,56441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →